Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib + topotecan + temozolomide in pediatric relapsed/refractory solid tumors
2024-512095-35-00Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2024
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 15
01
Overview
Phase 2, open-label, single-arm trial of ribociclib, topotecan and temozolomide in neuroblastoma, medulloblastoma, high-grade glioma (HGG) and 2 more, sponsored by Novartis. Primary endpoints: Incidence of dose-limiting toxicities (DLTs) in Cycle 1, Objective response rate (ORR) by BIRC and 1 more. Started Apr 2024; status: completed.
02
Drugs
ribociclibtopotecantemozolomide
03
Conditions
neuroblastomamedulloblastomahigh-grade glioma (HGG)malignant rhabdoid tumor (MRT)rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on 2024-512095-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512095-35-00.